Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
 

_____ Brought to you by Mac-Mod Analytical _____

Winning the biologics race: Strategies for overcoming separation challenges

REGISTER NOW

 

  November 6, 2019

  10:00 a.m. PST, 1:00 p.m. EST, 18:00 GMT, 19:00 CET

 

Overview

 

The landscape for new biological drug development continues to evolve in complexity. With biosimilars entering the market and originator products coming off patent, the competitive race for market dominance is reliant on:
1. A deeper understanding of the drug product to produce a more comprehensive drug filing in order to delay or prevent market entrance by a competitor.
2. A more thorough characterization of an innovator product or proposed biosimilar in order to take full advantage of the Regulatory pathways to rapid approval.

Pharmaceutical companies employ many orthogonal techniques and methodologies to better develop a complete picture of biopharmaceuticals which are inherently more complex than small molecules. The use of various separation technologies in the analysis of biological drugs is pervasive in the overall new product development. While not all separations involve HPLC, most do and would benefit from the unique characteristics of superficially porous particle columns. This webinar will walk through the biological drug development process, while focusing on the unique separation needs of biologicals, including a conversation on intact and reduced mAb mass analysis by LC/MS. The webinar will also demonstrate a way to develop an understanding of the protein backbone via peptide mapping and glycosylation while emphasizing areas in the workflow where superficially porous particle columns with appropriate pore sizes offer a unique advantage.

Brought to you by:

 

Key Learning Objectives

  • Why is it important to fully characterize a new or biosimilar product?
  • What is required to fully characterize a biopharmaceutical product?
  • How to enable the characterization of a biopharmaceutical product through better chromatography (benefits of improved column technology such as superficially porous particle (SPP) columns) in the workflow with examples.

Who Should Attend

  • Separation scientists involved in developing LC and LC/MS characterization methods of biopharmaceutical products and those interested in learning more about separation challenges in this industry.
 

Speaker

Joseph L. Glajch, Ph.D.
President
JLG AP Consulting LLC
 

Moderator

Jeff Huber
Contributing Editor,
C&EN Media Group
 

REGISTER NOW